

PRODUCT INFORMATION

NPS 2143 (hydrochloride)

Item No. 17903

CAS Registry No.: 324523-20-8

Formal Name: 2-chloro-6-[(2R)-3-[[1,1-dimethyl-2-(2-naphthalenyl)ethyl]amino]-2-hydroxypropoxy]benzonitrile, monohydrochloride

Synonym: SB-262470A

MF: $C_{24}H_{25}ClN_2O_2 \cdot HCl$

FW: 445.4


Purity: $\geq 98\%$

UV/Vis.: λ_{max} : 225 nm

Supplied as: A crystalline solid

Storage: $-20^\circ C$

Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

NPS 2143 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the NPS 2143 (hydrochloride) in the solvent of choice. NPS 2143 (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of NPS 2143 (hydrochloride) in ethanol is approximately 2 mg/ml and approximately 30 mg/ml in DMSO and DMF.

NPS 2143 (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, NPS 2143 (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. NPS 2143 (hydrochloride) has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Calcium-sensing receptor (CaSR) is a G protein-coupled receptor that is involved in calcium homeostasis.^{1,2} Activation of CaSR on parathyroid cells decreases the secretion of parathyroid hormone (PTH), which in turn reduces blood calcium concentration.^{1,2} NPS 2143 is a potent and selective antagonist of CaSR ($IC_{50} = 43$ nM) that stimulates PTH secretion from parathyroid cells *in vitro* ($EC_{50} = 39$ nM).^{3,4} It is effective *in vivo*, causing a sustained increase in plasma PTH in rats when given intravenously.^{3,4} Daily oral administration of NPS 2143 to osteopenic ovariectomized rats results in a dramatic increase in bone turnover, as well as increased circulating PTH levels.³

References

1. Nemeth, E.F. *J. Mol. Endocrinol.* **29**, 15-21 (2002).
2. Filopanti, M., Corbetta, S., Barbieri, A.M., *et al. Clin. Cases Miner. Bone Metab.* **10**(3), 162-165 (2013).
3. Gowen, M., Stroup, G.B., Dodds, R.A., *et al. J. Clin. Invest.* **105**, 1595-1604 (2000).
4. Nemeth, E.F., DelMar, E.G., Heaton, W.L., *et al. JPET* **299**(1), 323-331 (2001).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM